Genenta Science
Biotechnology company that develops gene transfer therapy for the treatment of cancer tumors.
Launch date
Employees
Market cap
€66.2m
Enterprise valuation
€47m (Public information from Sep 2024)
Share price
$3.85 GNTA
Company register number MI2045555
Milan Lombardy (HQ)
Financials
Estimates*
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| EBITDA | (5.6m) | (5.5m) | (13.3m) | (11.5m) | (19.0m) | (30.3m) | (38.1m) |
| Profit | (5.6m) | (5.5m) | (8.5m) | (11.6m) | (18.5m) | (24.1m) | (29.9m) |
| EV / EBITDA | - | -31.7x | -7.0x | -7.1x | -3.4x | -2.1x | -1.7x |
| R&D budget | 4.7m | 3.4m | 5.3m | 6.5m | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
$7.2m | Series A | ||
$3.8m | Series A | ||
* | €7.0m | Series B | |
* | €13.2m | Early VC | |
* | N/A | $40.0m | IPO |
| Total Funding | €30.2m | ||
Related Content
Recent News about Genenta Science
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.